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AbstrACt Osteopontin (OPN) is a multifunctional glycophosphoprotein secreted 
by many cell types, including osteoblasts, lymphocites, macrophages, epithelial cells, 
and vascular smooth muscle cells. It has been implicated in many physiological and 
pathological processes, such as cell-mediated immunity, inflammation, cell surviv-
al, and tumor invasion and metastasis. Osteopontin has multiple emerging roles in 
cutaneous biology and pathology and OPN involvement has been emphasized in 
Th1-mediated diseases such as psoriasis. Alopecia areata (AA) is a form of non-scar-
ring hair loss affecting anagen stage hair follicles with a multifactorial autoimmune 
pathogenesis characterized by a prevalent Th1 cytokine profile. Given the role of 
osteopontin in Th1-mediated inflammation, we have postulated that OPN may be 
involved in AA pathogenesis. The aim of our study was to investigate plasma OPN 
level in alopecia areata before and after DPCP treatment. Our results showed that 
OPN plasma levels in patients with alopecia areata were higher than in healthy con-
trols, but patients achieving complete recovery after DPCP treatment did not show a 
statistically significant reduction of OPN plasma levels.
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INtrOduCtION
Alopecia areata (AA) is a type of non-scarring hair 
loss affecting anagen stage hair follicles with a multi-
factorial autoimmune pathogenesis and an unknown 
etiology (1).
It affects about 2-3% of new patients attending 
Dermatology Clinics, presenting a wide range of clini-
cal heterogeneity (1).
AA involves the scalp and any hair-bearing body 
surface, with possible nail localization in 10% of pa-
tients. A wide spectrum of clinical presentation can oc-
cur – from single or multiple patches of hair loss to a 
complete hair loss on the scalp (alopecia totalis) or the 
entire body (alopecia universalis); the affected skin ap-
pears normal or slightly erythematous and edematous. 
Most cases of alopecia areata resolve spontaneously 
within 1 year, but up to 25% develop into severe forms 
such as alopecia totalis and alopecia universalis (1,2).
Topical immunotherapy with 2,3-diphenilcyclo-
propenone (DPCP) has shown to be one of the most 
effective treatments for severe and refractory AA and 
to be able to modify the “cytokine storm” (3). 
Although many molecular pathways are impli-
cated in AA immune-pathogenesis, Th1 cytokine pro-
file seems to play a crucial role: a greater expression 
of interferon gamma (IFN-γ), interleukin 1 (IL-1), and 
tumor necrosis factor alpha (TNF-α) has been exten-
sively shown in serum and tissue of patients with AA 
compared to healthy controls (1-4).
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Osteopontin (OPN), also known as early T lym-
phocyte activation 1 (Eta-1), is a phosphorylated acid 
glycoprotein firstly identified as a bone component 
involved in bone formation and calcification. It is se-
creted by osteoblasts, lymphocytes, macrophages, 
keratinocytes, and vascular smooth cells (4,5). Osteo-
pontin is also implicated in cell-mediated immunity, 
cell survival, inflammation, and tumor invasion and 
metastases (6-7).
High circulating OPN levels have been reported in 
several dermatological and non-dermatological dis-
eases, but data on OPN expression in patients with 
alopecia areata are not available in the literature (8).
Therefore, given the role of osteopontin in Th1-
mediated inflammation, we have postulated that 
OPN may be involved in the pathogenesis of AA.
The aim of our study was to investigate plasma 
OPN level in alopecia areata before and after DPCP 
treatment.
PAtIeNts ANd MethOds
design of the study
The study is a retrospective case-control analysis 
approved by the Polytechnic Marche University Ethi-
cal Committee and conducted in accordance with the 
Declaration of Helsinski (9).
Population
Among blood samples stored at -80°C in our se-
rum/plasma bank, we selected the following samples: 
40 patients affected by alopecia areata (23 men and 
17 women; mean age 40.25±6.35; range 20-55), both 
before (T0) and after twelve months (T12) of treat-
ment with DPCP, and twenty controls obtained from 
healthy subjects matched for sex and age.
Blood samples of patients who had had a clini-
cal recurrence of disease after DPCP discontinuation 
were also retrieved.
Although not an exclusion criterium, neither fa-
miliar history of AA nor personal history of atopy or 
autoimmune disease, including thyroiditis, had been 
reported in the patient group.
diagnosis of alopecia areata
Diagnosis of alopecia areata had been made by 
a trained dermatologist based on the clinical evalu-
ation of a diffuse or patchy alopecia and the presence 
of exclamation mark hairs. In patchy AA the severity 
of hair shedding had been evaluated by a pull test on 
three separate areas of the scalp: an extraction of six 
or more hairs was considered a positive pull test (10).
The images stored from a previous video-derma-
toscopic evaluation were retrieved to evaluate the 
most common signs of alopecia areata: yellow dots 
(hair follicles filled with hyperkeratotic plugs), black 
dots (hair follicles containing cadaverized hairs), bro-
ken hairs, exclamation point hairs, clustered short 
vellus hairs, and their changes after treatment with 
DPCP (11).
All the enrolled patients with AA had not respond-
ed to any previous topical and intralesional cortico-
steroid therapy; thus after a four-weeks wash out 
period, they received DPCP following the protocol 
proposed by Happle et al. (12).
The DPCP concentrations had been progressively 
increased until erythema and/or pruritus appeared 
and was maintained for 36-48 hours after application. 
This dose was then considered the gold standard, 
and patients were asked to apply it until complete 
recovery.
Figure 1. Osteopontin plasma levels in patients with 
AA in comparison with healthy controls.
Figure 2. Osteopontin plasma levels in patients with 
AA before and after DPCP treatment in comparison 
with healthy controls.
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Laboratory assays
Venous blood samples had been drawn after an 
overnight fast at baseline (T0, before DPCP treatment) 
and after twelve months of DPCP application. 
OPN quantitative determination was done 
through a solid phase sandwich ELISA kit on EDTA 
plasma samples. This assay kit precoats a monoclonal 
antibody specific for OPN onto a microplate to bind 
OPN in the samples. All blood samples had been pre-
served at -80°C. Plasma samples were dilated and the 
immunoassay was performed according to the man-
ufacturer’s instructions. 
statistical analysis
All data were analyzed using Graph-Pad Prism 
(version 5.0, El Camino REAL, San Diego, CA) and 
QuickCalcs software package. Data were expressed 
as means±SD. The normal distribution of continuous 
variables was verified with the Kolmogorov-Smirnov 
test, and statistical analyses included the Mann-Whit-
ney test for continuous variables. Linear regression 
was used to model the relationship between vari-
ables. For all the analyses, a P-value <0.05 was consid-
ered to be statistically significant.
resuLts
In the group of patients with AA, thirty-one pa-
tients had patchy alopecia (<50% scalp involvement) 
and nine alopecia totalis; the mean time of the onset 
of the disease was 4.05±2.37 months. 
In three patients treatment was discontinued for 
severe acute contact dermatitis after sensitization 
with DPCP 2%. Thirty-seven patients completed the 
treatment, showing initial hair regrowth after twelve 
weeks of DPCP and obtaining a complete recovery af-
ter a mean period of 12 months. 
Thirty-three patients maintained these satisfac-
tory results for almost twelve months following the 
discontinuation of DPCP treatment; four patients 
with patchy AA developed a recurrence three months 
after DPCP discontinuation.
At baseline, the mean plasma OPN value in pa-
tients with AA was significantly higher than in healthy 
controls (85.25±46.48 ng/mL vs. 46.60±26.33 ng/mL; 
P=0.0077) (Figure 1); however, plasma levels of OPN 
did not correlate with severity and duration of AA.
There was no statistically significant decrease 
of mean plasma levels of OPN (73.59±27.48 vs 
85.25±46.48, P>0.05) after DPCP treatment, although 
it was significantly higher than in healthy subjects 
(73.59±27.48 vs. 46.60±26.33 ng/mL, P=0.0084) 
(Figure 2).
Additionally, in the subgroup of patients with 
recurrent AA, relapse was associated with increased 
plasma levels of OPN, levels of which tended towards 
those found at T0 (mean: 76.00±13.67 ng/mL).
dIsCussION
Osteopontin is a multifunctional protein that plays 
an important role in inflammatory processes inhibit-
ing Th2 response and promoting Th1 cytokine func-
tion, with a crucial role in leukocyte migration (7,8).
Our study shows that OPN plasma levels in pa-
tients with AA were higher than in healthy controls, 
and it could be hypothesized that osteopontin has a 
role in the pathogenesis of alopecia areata, amplify-
ing the inflammatory cascade.
Alopecia areata is considered a Th1-mediated skin 
disease, for which topical immunotherapy with 2,3-
diphenilcyclopropenone (DPCP) has shown to be one 
of the most effective treatments, even though thera-
peutic response differs from patient to patient. DPCP 
is a potent contact sensitizer, whose mechanism of 
action in AA is not yet completely understood; how-
ever, a hypothesis based on cytokine inhibitors pro-
poses a possible interference of DPCP with pre-exist-
ing pro-inflammatory cytokines and their continued 
production by follicular keratinocytes (5,10).
In our case series, patients obtaining complete 
recovery after DPCP treatment did not show a sta-
tistically significant reduction of OPN plasma levels. 
It could be inferred that DPCP acts primarily on the 
skin without any significant interference on systemic 
levels.  
However, it is interesting to note that OPN plasma 
level increases in patients with alopecia areata recur-
rence after DPCP discontinuation, whereas a statisti-
cal significant difference between OPN values has 
not been found before and after the DPCP treatment. 
Based on these data, it is not possible assuming OPN 
as a predictive marker of disease, taking into account 
the unpredictability and intensity of the relapse of AA 
(13).
Furthermore, OPN expression has been shown 
to be linked to vitamin D levels in bone and kidney-
stone formation. Currently the primary deficit of vi-
tamin D is considered crucial for the development of 
autoimmune disease, such as alopecia areata. Thus, 
we could hypothesize that increased serum levels 
of OPN could be a primitive facilitating factor in AA 
pathogenesis, possibly acting together with vitamin 
D deficiency (14,15).
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CONCLusION
This is the first pilot study suggesting a possible 
involvement of osteopontin in AA pathogenesis; fur-
ther and larger prospective studies are needed in or-
der to achieve in-depth knowledge of the role of OPN 
in AA.
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